nvp pdf 713 profile

ID Source	ID
PubMed CID	9690139
CHEMBL ID	221667
SCHEMBL ID	13681832
MeSH ID	M0468818

Synonym
lbm-415
vic-104959
nvp-pdf-713
CHEMBL221667
478913-91-6
l-prolinamide, (2r)-2-butyl-n-formyl-n-hydroxy-beta-alanyl-n-(5-fluoro-1-oxido-2-pyridinyl)-
lbm 415
unii-027g8kn47f
(2s)-1-((2r)-2-((formylhydroxyamino)methyl)hexanoyl)pyrrolidine-2-carboxylic acid n-(5-fluoro-1-oxopyridin-2-yl)amide
027g8kn47f ,
l-prolinamide, (2r)-2-butyl-n-formyl-n-hydroxy-.beta.-alanyl-n-(5-fluoro-1-oxido-2-pyridinyl)-
SCHEMBL13681832
lbm415
gtpl11043
nvp lbm-415
pdf-713
(2s)-n-(5-fluoro-1-hydroxypyridin-2-ylidene)-1-[(2r)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide
Q27231499
PD129054

Excerpt	Reference	Relevance
" After the completion of chemical synthesis, all the compounds were evaluated through in vitro antibacterial activity assay, some of which were further subject to in vivo rat pharmacokinetic assessment."	( New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment. Chen, C; Hu, W; Lv, F; Tang, Y; Wei, J; Zhu, T, 2016)	0.43

Bioassays (154)

Assay ID	Title	Year	Journal	Article
AID279267	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572497	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in BALB/c mouse pneumonia model assessed as reduction in lung bacterial load at 20 mg/kg, po administered twice daily 3 days starting 16 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID1311244	Antibacterial activity against Escherichia coli 14-2	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279208	Antibacterial activity against Streptococcus pneumoniae 19 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279226	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 1077 with PDF D176N mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279271	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572275	AUC in CD1 mouse at 5 mg/kg, iv by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279224	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3009 with PDF G69V mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279219	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 19 with after 14 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID565342	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS13 harboring pSW1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID572496	Drug concentration at time zero in CD1 mouse at 5 mg/kg, iv by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID283658	Antimicrobial activity against Haemophilus influenzae NB65044 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.
AID572273	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279254	Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311235	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-4	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID565346	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS30 harboring pRC5 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID572487	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae ATCC 700677 infected in po dosed BALB/c mouse administered twice daily for 3 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID572269	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 49951 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279204	Antibacterial activity against Streptococcus pneumoniae 1077 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279205	Antibacterial activity against Streptococcus pneumoniae 3665 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572279	Cmax in CD1 mouse at 20 mg/kg, po by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID565175	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS6 expressing nfxB A115C, T39P mutant by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279262	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569342	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID283660	Antimicrobial activity against Haemophilus influenzae CDS23 mutant overexpressing Def by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.
AID483193	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by microbroth dilution technique	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311232	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-1	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID1311246	Antibacterial activity against Escherichia coli 14-2 expressing extended-spectrum beta-lactamase	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID572485	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NB01021 infected in po dosed BALB/c mouse administered 0, 4, 23 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID572270	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID1311242	Antibacterial activity against Enterococcus faecalis 14-5	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279210	Antibacterial activity against Streptococcus pneumoniae 2527 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279270	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279258	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID565169	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 NB52019 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279217	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3243 with PDF G69C, Q172H mutation after 20 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569346	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID565173	Antibacterial activity against Pseudomonas aeruginosa PAO1 NB52020 expressing mexAB-oprM by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279232	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311240	Antibacterial activity against Enterococcus faecalis 14-2	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID565347	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS22 expressing mexAB-oprM folD A424C, T142P mutant by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279213	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3009 with PDF G69V mutation after 14 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311224	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-1	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID572282	Antimicrobial activity against methicillin susceptible Staphylococcus aureus ATCC 49951 infected in po dosed NMRI mouse treated 1 and 5 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID483196	Antibacterial activity against Escherichia coli ATCC 35218 by microbroth dilution technique	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID572489	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in BALB/c mouse pneumonia model assessed as reduction in lung bacterial load at 80 mg/kg, po administered twice daily 3 days starting 16 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279263	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572490	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in BALB/c mouse pneumonia model assessed as reduction in lung bacterial load at 40 mg/kg, po administered twice daily 3 days starting 16 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279234	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3413 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279265	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279206	Antibacterial activity against Streptococcus pneumoniae 3243 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569344	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311237	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-2	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279257	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID483191	Antibacterial activity against Staphylococcus aureus ATCC 25923 by microbroth dilution technique	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID279222	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 37 with PDF G69R, P76R mutation after 50 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569348	Antibacterial activity against Haemophilus influenzae by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311238	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-3	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID572278	AUC in CD1 mouse at 20 mg/kg, po by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID572488	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae ATCC 700677 infected in sc dosed BALB/c mouse administered twice daily for 3 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID565172	Antibacterial activity against Pseudomonas aeruginosa PAO1 NB52023 expressing mexB and mexX by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279209	Antibacterial activity against Streptococcus pneumoniae 24 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279203	Antibacterial activity against Streptococcus pneumoniae 1076 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID577987	Antimicrobial activity against Shigella flexneri 92475 after 24 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors.
AID279216	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3665 with after 27 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279218	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3676 with PDF R135C mutation after 20 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279272	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569340	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by broth micro dilution technique	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID565341	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS13 expressing mexAB-oprM fmt C127T, R43C mutant by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID565170	Antibacterial activity against Pseudomonas aeruginosa PAO1 NB52021 expressing mexB by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID577984	Antimicrobial activity against Streptococcus pneumoniae 31002 after 24 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors.
AID565352	Induction of mexXY (PA5471) gene expression in wild type Pseudomonas aeruginosa PAO1 NB52019 at 12 ug/ml relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID565348	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS22 harboring pRC5 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID572281	Bioavailability in CD1 mouse at 5 mg/kg, iv by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID572286	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NB01021 infected in sc dosed BALB/c mouse administered 0, 4, 23 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID565339	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS28 expressing 16-bp deleted fmt at position 833 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279261	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID283661	Antimicrobial activity against Haemophilus influenzae CDS40 mutant with acrB insertional inactivation by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.
AID572493	Antimicrobial activity against multiple drug resistant Staphylococcus aureus NB01021 infected in immunocompetent NMRI mouse soft tissue infection model assessed as reduction in thigh bacterial load at 5.6 mg/kg, po administered thrice a day for 2 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID565344	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDR2 expressing mexAB-oprM and fmt::aacC1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID577986	Antimicrobial activity against Shigella boydii 51313 after 24 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors.
AID565349	Induction of mexY (PA2018) gene expression in wild type Pseudomonas aeruginosa PAO1 NB52019 at 12 ug/ml relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279268	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311230	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-3	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID572272	Antimicrobial activity against Streptococcus pneumoniae ATCC 6301 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID572276	Clearance in CD1 mouse at 5 mg/kg, iv by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279266	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279223	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3413 after 14 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311236	Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 14-1	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID577985	Antimicrobial activity against Streptomyces albus 260101 after 24 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors.
AID572284	Antimicrobial activity against methicillin susceptible Staphylococcus aureus ATCC 13709 infected in po dosed NMRI mouse treated 1 and 5 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID572271	Antimicrobial activity against methicillin-resistant Staphylococcus aureus NB01021 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279256	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279214	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 1076 with PDF D176N mutation after 39 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID565345	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS30 expressing folD G493T, V165R mutant by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279221	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 2527 after 27 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572277	Volume of distribution at steady state in CD1 mouse at 5 mg/kg, iv by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279229	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3676 with PDF R135C mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569341	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 12228 by broth micro dilution technique	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID565353	Induction of oprM (PA0427) gene expression in wild type Pseudomonas aeruginosa PAO1 NB52019 at 12 ug/ml relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID483194	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by microbroth dilution technique	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID565174	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS1 expressing 14-bp deleted nfxB at base 92 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279260	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID565350	Induction of mexX (PA2019) gene expression in wild type Pseudomonas aeruginosa PAO1 NB52019 at 12 ug/ml relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID1311245	Antibacterial activity against Escherichia coli 14-1 expressing extended-spectrum beta-lactamase	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID565351	Induction of mexZ (PA2020) gene expression in wild type Pseudomonas aeruginosa PAO1 NB52019 at 12 ug/ml relative to control	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID483195	Antibacterial activity against Escherichia coli ATCC 25922 by microbroth dilution technique	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID279225	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 1076 with PDF D176N mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572486	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in po dosed NMRI mouse administered thrice daily for 4 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID577983	Antimicrobial activity against Staphylococcus aureus 26003 after 24 hrs by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5	Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogs as peptide deformylase inhibitors.
AID1311226	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-4	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279220	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 24 with PDF G139F mutation after 27 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279212	Antibacterial activity against Streptococcus pneumoniae 3413 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572274	Antimicrobial activity against multiple drug-resistant Streptococcus pneumoniae ATCC 700677 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID569339	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth micro dilution technique	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311234	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-3	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID569347	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311243	Antibacterial activity against Escherichia coli 14-1	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279233	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 37 with PDF G69R, P76R mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279259	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279211	Antibacterial activity against Streptococcus pneumoniae 37 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311241	Antibacterial activity against Enterococcus faecalis 14-3	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279255	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311233	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 14-2	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID569338	Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth micro dilution technique	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311239	Antibacterial activity against Enterococcus faecalis 14-1	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID572491	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in BALB/c mouse pneumonia model assessed as complete eradication of bacteria at 40 mg/kg, po administered twice daily 3 days starting 16 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279264	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572492	Antimicrobial activity against Streptococcus pneumoniae ATCC 6303 infected in po dosed BALB/c mouse pneumonia model assessed as complete eradication of bacteria administered twice daily 3 days starting 16 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279269	Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID483192	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by microbroth dilution technique	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID572283	Antimicrobial activity against methicillin susceptible Staphylococcus aureus ATCC 49951 infected in sc dosed NMRI mouse treated 1 and 5 hrs post infection	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID565171	Antibacterial activity against Pseudomonas aeruginosa PAO1 NB52022 expressing mexX by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID569345	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID279215	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 1077 with PDF D176N mutation after 24 passages by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279207	Antibacterial activity against Streptococcus pneumoniae 3676 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID283659	Antimicrobial activity against Haemophilus influenzae CDS01 mutant with acrB insertional inactivation by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.
AID1311225	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-2	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID572494	Antimicrobial activity against multiple drug resistant Staphylococcus aureus NB01021 infected in immunocompetent NMRI mouse soft tissue infection model assessed as reduction in thigh bacterial load at 16.7 mg/kg, po administered thrice a day for 2 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279273	Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572280	Tmax in CD1 mouse at 20 mg/kg, po by liquid chromatography/mass spectroscopy	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID1311231	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-4	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279230	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 19 with after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID569343	Antibacterial activity against methicillin-resistant Staphylococcus aureus by agar dilution method	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.
AID1311227	Antibacterial activity against methicillin-resistant Staphylococcus aureus 14-5	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279231	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 24 with PDF G139F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311228	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-1	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID565340	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDS28 harboring pSW1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
AID279228	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3243 with PDF G69C, Q172H mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID572495	Antimicrobial activity against multiple drug resistant Staphylococcus aureus NB01021 infected in immunocompetent NMRI mouse soft tissue infection model assessed as reduction in thigh bacterial load at 50 mg/kg, po administered thrice a day for 2 days	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
AID279202	Antibacterial activity against Streptococcus pneumoniae 3009 by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1311229	Antibacterial activity against methicillin-sensitive Staphylococcus aureus 14-2	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.
AID279227	Antibacterial activity against LBM145 resistance selected Streptococcus pneumoniae 3665 with after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID565343	Antibacterial activity against Pseudomonas aeruginosa PAO1 CDR1 expressing fmt::aacC1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (50.00)	29.6817
2010's	4 (50.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.46	2	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.03	1	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.75	3	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	2.05	1	penicillin allergen; penicillin
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.75	3	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.46	2	penicillin allergen; penicillin	antibacterial drug
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.44	2	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.03	1	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.47	2	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	2.44	2	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
linezolid [no description available]	2.75	3	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2.03	1
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.03	1	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
hmr 3647 [no description available]	2.05	1
cefuroxime [no description available]	2.03	1	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	2.03	1	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefdinir [no description available]	2.03	1	cephalosporin; ketoxime	antibacterial drug
gsk1322322 GSK1322322: inhibits peptide deformylase; structure in first source	2.13	1
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.03	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.13	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies
Infections, Pneumococcal [description not available]	2.03	1
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	2.03	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.05	1
Pneumonia Infection of the lung often accompanied by inflammation.	2.05	1

nvp pdf 713

Cross-References

Synonyms (19)

Research Excerpts

Pharmacokinetics

Bioassays (154)

Research

Studies (8)

Study Types

nvp pdf 713

Cross-References

Synonyms (19)

Research Excerpts

Pharmacokinetics

Bioassays (154)

Research

Studies (8)

Study Types

Related Drugs (20)

Related Conditions (4)